BetterLife PharmaBETRF +11.06%28 EBIT per Share is $-0.01 as of Apr. 2026. GuruFocus rates BETRF with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,178 Biotechnology companies, BetterLife Pharma ranks better than 87.27% on this metric.
BetterLife Pharma's EBIT per Share for the
three
months ended in Apr. 2026 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 51.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 45.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 35.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BetterLife Pharma's EBIT per Share or its related term are showing as below:
BETRF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -618.4 Med: 34 Max: 53.8
Current: 51.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BetterLife Pharma was 53.80% per year. The lowest was -618.40% per year. And the median was 34.00% per year.
BETRF's 3-Year EBIT Growth Rate is ranked better than 87.27% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs BETRF: 51.80
BetterLife Pharma (OTCPK:BETRF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BetterLife Pharma EBIT per Share Related Terms
BetterLife Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for BetterLife Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BetterLife Pharma (BETRF) has a EBIT per Share of $-0.01 as of Apr. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BetterLife Pharma and its competitors. According to the industry distribution chart, BetterLife Pharma ranks #150 out of 1178 companies in the Biotechnology industry, placing it in the top 12.7%.
Is BetterLife Pharma's EBIT per Share too high?
BetterLife Pharma's current EBIT per Share is $-0.01. Based on the distribution chart, BetterLife Pharma ranks #150 out of 1178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BetterLife Pharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BetterLife Pharma ranks #150 out of 1178 companies for EBIT per Share. This places BetterLife Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BetterLife Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BetterLife Pharma's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. BetterLife Pharma's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current EBIT per Share is $-0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
28GF Score
Get the complete analysis for BETRF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BETRF has been successfully added to your 
